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Abstract: This study investigated whether the 21-aminosteroid U74389F, an inhibitor of lipid perox-
idation, attenuates pathophysiologic changes in experimental pneumococcal meningitis. Infected rats
injected intravenously with vehicle and U74389F developed increases in regional cerebral blood flow
(rCBF), intracranial pressure (ICP), brain water content, and white blood cells (WBC) in cerebrospinal
fluid (CSF) within 8 h after intracisternal challenge. Pretreatment with or administration of U74389F 4
h after infection significantly reduced the increase in ICP but had no effect on rCBF increase. Moreover,
U74389F pretreatment significantly reduced brain water content and CSF WBC count. In vitro, U74389F
inhibited iron-dependent lipid peroxidation of astrocyte cultures and the production of tumor necrosis
factor-a, interleukin-6, and nitric oxide by stimulated macrophages. These data suggest that U74389F
modulates early pathophysiologic alterations in experimental pneumococcal meningitis
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This study investigated whether the 21-aminosteroid U74389F, an inhibitor of lipid peroxidation,
attenuates pathophysiologic changes in experimental pneumococcal meningitis. Infected rats in-
jected intravenously with vehicle and U74389F developed increases in regional cerebral blood flow
(rCBF), intracranial pressure (ICP), brain water content, and white blood cells (WBC) in cerebrospi-
nal fluid (CSF) within 8 h after intracisternal challenge. Pretreatment with or administration of
U74389F 4 h after infection significantly reduced the increase in ICP but had no effect on rCBF
increase. Moreover, U74389F pretreatment significantly reduced brain water content and CSF WBC
count. In vitro, U74389F inhibited iron-dependent lipid peroxidation of astrocyte cultures and the
production of tumor necrosis factor-a, interleukin-6, and nitric oxide by stimulated macrophages.
These data suggest that U74389F modulates early pathophysiologic alterations in experimental
pneumococcal meningitis.
Animal models of bacterial meningitis have increased our
knowledge of the complex pathophysiologic mechanisms of
the disease [1-5]. In a rat model of meningitis, we showed
that intracisternal (ic) inoculation of live pneumococci or pneu-
mococcal cell wall components induces an early increase in
regional cerebral blood flow (rCBF), intracranial pressure
(lCP), and brain water content [6]. Pretreatment with free su-
peroxide dismutase (SOD), polyethylene glycol (PEG)-conju-
gated SOD, deferoxamine, and catalase greatly attenuates these
pathophysiologic changes; the strongest effects are shown with
SOD and PEG-SOD [6-8]. Findings by other investigators
support a role for reactive oxygen species in the pathophysiol-
ogy of bacterial meningitis [9, 10]. Cellular injury caused by
reactive oxygen species may involve direct damage to proteins
and DNA as well as lipid peroxidation [11]. Here we tested
the effect of the novel 21-aminosteroid U74389F [12, 13], an
inhibitor of lipid peroxidation, for its capacity to alter rCBF,
ICP, and brain edema formation and to reduce meningeal in-
flammation in experimental pneumococcal meningitis.
Materials and Methods
Animal preparation. We used a well-characterized rat menin-
gitis model that has been described in detail [6]. Adult male Wistar
rats (250- 330 g) were intraperitoneally anesthetized with 100 mg!
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kg thiobutabarbiturate (lnactin; Byk Gulden, Konstanz, Germany),
tracheotomized, and artificially ventilated (small animal ventilator,
model 683; Harvard, South Natick, MA). End-expiratory CO 2 was
continuously monitored by infrared CO 2 analyzer (model 2200;
Heyer, Bad Ems, Germany). Mean arterial blood pressure (MABP)
was measured by pressure transducer (Statham P23; Viggo-Spec-
tramed, Oxnard, CA) connected to the femoral artery cannula.
Arterial blood gases and hematocrit were determined before ic
inoculation and every 2 h thereafter (gas check model 1304; Instru-
mentation Laboratory, Kirchheim, Germany). Body temperature
was maintained at 38°C by a rectal thermometer-controlled heat-
ing pad. Rats were placed in a stereotaxic frame, and a burr hole
was made in the occipital bone for placement of the cisterna magna
catheter. A 5-mm-diameter craniotomy was made in the right pari-
etal bone for the placement of a laser-Doppler probe. rCBF was
measured continuously by laser-Doppler flowmetry (model BPM
403a; Vasamedics, St. Paul, MN). Changes in rCBF were ex-
pressed as percent changes from baseline. The dura was left intact
in all preparations.
Cerebrospinal fluid (CSF; 100 ILL) was withdrawn through the
cisterna magna catheter, and meningitis was induced by ic injection
of 100 p,L of pneumococci (=106 cfu). We used Streptococcus
pneumoniae type 3 (no. 17260), an isolate from an endotracheal
aspiration of a patient with septic infection that was maintained at
-20°C in trypticase soy broth (Oxoid, Wesel, Germany) supple-
mented with 10% glycerol and 1% IsoVitale (Becton Dickinson
Microbiology Systems, Heidelberg, Germany). Before use, the
bacteria were subcultured on blood-agar plates, checked for purity,
inoculated into brain-heart infusion broth (Oxoid), supplemented
with 3% horse serum and 1% bovine albumin (Serva, Heidelberg,
Germany), and incubated overnight at 35°C. The broth was centri-
fuged for 20 min at 2500 g, and the sediment was washed once
with 0.85% saline and resuspended in saline. The final suspension
was turbidimetrically adjusted to an optical density of 0.5 at 546
nm (photometer with 13-mm filter; Eppendorf, Hamburg, Ger-
many), thus achieving a concentration of = 107 cfulmL.
The following parameters were continuously monitored for 8 h
after ic injection by a personal computer system after analog-
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digital conversion for signal processing: ICP (measured by Statham
P23 pressure transducer connected to the cisterna magna catheter),
rCBF, and MABP. Blood and CSF white blood cell (WBC) counts
were determined at baseline and 4 and 8 h after ic injection. At
the end of the experiment, the reactivity of the cerebral circulation
to CO 2 was tested. Hypercapnia was produced with 10% CO2,
21% O2 , and the balance of N 2 . Before and 10 min after hypercap-
nia, arterial blood samples were drawn for blood gas and pH
analysis. To determine brain water content, brains were weighed
in glass dishes then dried for 16 h at 130°C to stable weight. Brain
water content was calculated by the formula [(wet weight - dry
weight)/wet weight] X 100 [6].
We studied 6 groups of rats: There were 6 infected rats in groups
1-3, 6 uninfected animals in group 4, and 3 and 4 infected rats
in groups 5 and 6, respectively. Animals in group I were injected
intravenously (iv) with vehicle of U74389F: 21-[ 4-(2,6-di-I-pyr-
rolidinyl-4-pyrimidinyl)-I-piperazinyl]-pregna-I,4,9 (II )-triene-
3,20-dione, monomethansulfonate (provided by Upjohn, Kalama-
zoo, MI). The vehicle was citric acid and citrate (U74389Fyeh) .
Group 2 animals were treated iv with U74389F 15 min before (3
mg/kg) and 2 h after (1.5 mg/kg) ic pneumococcal challenge. Rats
in group 3 were treated iv with U74389F 4 h after (3 mg/kg) and
6 h after (1.5 mg/kg) ic infection. Group 4 rats were injected iv
with U74389F 15 min before (3 mg/kg) and 2 h after (1.5 mg/kg)
ic injection of PBS. Rats in group 5 were treated iv with U74389F
15 min before (30 mg/kg) and 2 h after (15 mg/kg) ic infection
(5-h measurement period). Group 6 rats were pretreated iv with
U74389F 15 min before (3 mg/kg) and 2 h after (1.5 mg/kg) ic
infection, the NO synthase inhibitor N-nitro-L-arginine (L-NA; 10
mg/kg) was administered iv 4 h after ic infection (5-h measurement
period).
In vitro experiments. We investigated whether U74389F is a
potent inhibitor of lipid peroxidation when central nervous system
(CNS) cells are used. For this purpose, primary rat astrocytes were
stimulated with heat-killed pneumococci; lipid peroxidation was
assessed by the formation ofthiobarbituric acid-reactive products.
The data were compared with those of methylprednisolone, a
known potent inhibitor of lipid peroxidation.
For initiation of lipid peroxidation, primary rat astrocytes were
incubated with 200 f-LM Fe3+ and 50 f-LM Fe 2 + in 0.9% saline for
0.5 h at 37°C [14]. Fe3 + and Fe2 + solutions (Aldrich Chemie,
Steinheim, Germany) were prepared fresh in argon-purged H20
and used immediately. Astrocytes and the supernatant were re-
moved, homogenized, and sonicated for 30 s. After centrifugation
(800 g, 5 min, 4°C), 150 f-LL of the cell suspension was incubated
with I mL of 0.5% thiobarbituric acid (Aldrich Chernie, Steinheim,
Germany) in 12.5% trichloracetic acid (Aldrich Chemie) for 10
min at 90°C. After samples were centrifuged (800 g, 5 min, room
temperature), the formation of thiobarbituric acid-reactive oxida-
tion products was determined at A 532 (Ultrospec III; Pharmacia
LKB, Freiburg, Germany). Quantification was based upon a molar
extinction coefficient of 1.56 X 105 [14]. The following groups
were investigated: addition of U74389F yc h (n = 16); U74389F,
100 f-LM (n = 6) and 1 mM (n = 6), 10 mM (n = 4); methylpredni-
solone vehicle (n = 6); methylprednisolone, 1 mM (n = 6) and
10 mM (n = 4); controls (n = 6; addition of the diluent of Fe2+/
Fe3+ plus U74389Fvc h ) .
Primary astrocyte cultures were prepared from the cerebral cor-
tex of I-day-old neonatal Wistar rats and grown on 6-well plates
(Falcon; Becton Dickinson, Plymouth, UK) at 37°C in a 5% CO2
incubator with 95% oxygen. During the first 7 days, the astrocytes
were maintained in Dulbeccos modified Eagle medium (DMEM)
supplemented with 20% heat-inactivated fetal calf serum (FCS).
On day 8, the medium was replaced and the astrocytes were main-
tained in DMEM plus 5% FCS. Astrocytes were cultivated in 6-
well plates in culture medium until confluence. When confluence
was documented (days 12-14), the astrocytes were shaken at 400
rpm for 3 h to remove microglia and oligodendrocytes. Astrocytes
were then maintained I day in G5 medium [15] to eliminate mi-
croglia and oligodendrocytes. Astrocyte cultures were character-
ized on the basis of morphologic criteria and by the expression of
glial fibrillary acidic protein (GFAP) as detected by immunostain-
ing. These primary astrocyte cultures consisted of >95% GFAP-
positive cells. We used only astrocytes without any passage. Before
stimulation, astrocytes were washed with PBS without Ca2+ and
Mg2 + and maintained in DMEM with 5% FCS without phenol red
and antibiotics.
Peritoneal macrophage cultures. We also questioned whether
the activity of U74389F was restricted to inhibition oflipid peroxi-
dation. Thus, we tested to see if it interfered with the production
of known mediators of bacterial meningitis, such as cytokines
and NO. Peritoneal macrophages were stimulated with heat-killed
pneumococci, lipopolysaccharide (LPS), and cytokines. Peritoneal
exudate cells were obtained from 8-week-old female Wi star rats
that were injected intraperitoneally with 6 mL of Brewer's thiogly-
collate medium 3 days before isolation. The cells were cultured
in DMEM (Biochrom, Berlin) supplemented with 1% FCS (Bio-
chrom), 10 f-Lg/mL gentamicin, and I mM N-acetyl-L-alanyl-L-
glutamine. Cells were stimulated with heat-killed (60°C, 4 h) unen-
capsulated pneumococci (HKP; isogenic mutant of S. pneumoniae
type 3, no. 17260) in three different concentrations (105, 106 , and
107 cfu/ml.), LPS (Escherichia coli 0127:B8; I f-Lg/mL) or murine
recombinant interferon-v (rIFN-y; 100 U/mL) plus murine recom-
binant tumor necrosis factor-a (rTNF-a; 10 ng/mL). Murine rTNF-
a and rIFN-y were both purchased from Boehringer (Mannheim,
Germany). E. coli LPS was obtained from Difco (Detroit). Cell
cultures were untreated or treated with U74389F (I, 10, or 100
f-LM) or U74389Fveh ' Interleukin (IL)-6 and TNF-a were measured
using 7TDI cells [16] and L-M cells [17], respectively. NO produc-
tion in the cell culture supernatant was assessed by measuring
nitrite, a stable metabolic product of NO, by the Griess reaction
[18].
Statistical methods. Data on rCBF, ICP, and CSF WBC count
obtained 4 and 8 h after ic pneumococcal challenge in rats injected
iv with U74389Fveh or U74389F (groups 1 and 2) were compared
by unpaired Student's t test; P values were corrected for repeated
measurements using the Bonferroni-Holm procedure. Data on
brain water content and CO 2 reactivity at 8 h after ic challenge
from groups I and 2 were compared by the unpaired Student's t
test. Data on rCBF, ICP, and CSF WBC count at 4 h after ic
challenge in infected rats injected iv with U74389F in two different
dosages (groups 2 and 5) were compared by unpaired Student's t
test. Data on rCBF, ICP, and CSF WBC count at 4 and 5 h after
ic challenge in infected rats injected iv with U74389F or with
U74389F plus L-NA (groups 2 and 6) were compared by unpaired
Student's t test; P values were corrected for repeated measurements
using the Bonferroni-Holm procedure. One-way analysis of vari-
ance and Student-Newman-Keuls multiple comparisons were used
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Table 1. Pathophysiologic parameters in different experimental groups of rats.
Regional cerebral blood Intracranial pressure CSF white blood cell count
flow (%) (mm Hg) (cells/pL) Brain water CO 2
content (%) reactivity*
Group 4h 8h 4h 8h 4h 8 h at 8 h at 8 h
Infected
U74389F veh injected 175.3 :±: 7.0 211.6 :±: 5.2 13.3 :±: 1.7 15.4:±: 1.2 2611 :±: 551 6710 :±: 729 79.09 :±: 0.03 1.38 :±: 0.56
U74389F pretreated 151.8 :±: 7.0 204.4 :±: 3.1 9.0 :±: 1.4 11.0:±: LOt 1095 :±: 163t 4297 ::±: 289 t 78.80 :±: 0.06 t 0.86 :±: 0.26
Uninfected, U74389F injected 107.9 :±: 5.6 115.6 :±: 6.5 2.1 :±: 0.3 3.8:±: 0.9 6 :±: 2 23 :±: 10 77.91 :±: 0.10 1.34 :±: 0.45
NOTE. Each group, n = 6.
* Change in regional cerebral blood flow (%)/change in Pco, (mm Hg).
t P < .05, vs. infected, U74389Fvch-injected rats.
to compare data on thiobarbituric acid reactive products. Differ-
ences were considered significant when P < .05. Data are ex-
pressed as mean ± SE.
Figure 1. Time course of regional cerebral blood flow (rCBF) and
intracranial pressure (lCP) in infected rats injected with U74389F or
its vehicle (U74389Fveh ) before infection. rCBF and ICP increased in
both groups. Statistical analysis was done 4 and 8 h after intracisternal
injection(arrows) by unpaired Student's t test. P values were corrected
for repeated measurements by Bonferroni-Holm procedure. Pretreat-
ment with U74389F significantly reduced increase in ICP 8 h after
infection (see table I). Data are mean ± SE.
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Physiologic variables. MABP, Paz, Pco-, pH, hematocrit,
and body temperature were normal throughout the experiment
in all groups (data not shown). Cerebrovascular COz reactivity
did not differ significantly between groups (table 1).
rCBF, ICP, brain water content, and CSF WBC count.
There was an increase in rCBF in U74389Fveh-injected infected
rats (group 1) from a baseline of 100% to 211.6% ± 5.2%
within 8 h after pneumococcal challenge (table 1; figure 1). In
infected rats pretreated with U74389F (group 2), the mean
values of rCBF at 4 and 8 h after ic injection did not differ
significantly from that of infected rats pretreated with
U74389Fveh (table 1).
rcp markedly increased in infected U74389Fveh-injected rats
(group 1) within 8 h after infection from a baseline of 3.6 ±
0.4 mm Hg to 15.4 ± 1.2 mm Hg (figure 1, table 1). Pretreat-
ment with U74389F (group 2) significantly attenuated the in-
crease in rcp at 8 h (table 1). There was no change in rCBF and
rcp in uninfected rats pretreated with U74389F and injected ic
with PBS (group 4; table 1). Pretreatment with U74389F (group
2) significantly reduced brain water content and CSF WBC
counts (P < .05; table 1).
The inhibitory effect ofU74389F (group 2) on ICl' and CSF
pleocytosis in infected rats was not enhanced when infected
rats were pretreated with the higher dosage ofU74389F (group
5). For example, at 4 h after infection, rcp was 10.7 ± 4.2
mm Hg in group 5 versus 11.0 :::!:::: 1.0 mm Hg in group 2, and
CSF WBC count was 1021 :::!:::: 305 versus 1095 :::!:::: 163 cells/
pL. There was also no effect on rCBF (171.1 % :::!:::: 26.0% vs.
151.8% :::!:::: 7.0% at 4 h after infection).
Compared with effects observed in U74389Fveh-injected rats
(group 1), the administration ofU74389F 4 h after ic infection
(group 3) significantly attenuated the increase in rcp (7.6 :::!::::
1.5 vs. 15.4 :::!:::: 1.2 mm Hg, groups 3 and 1, respectively) but
Results
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Table 2. Effect of different doses of U74389F on the production of nitric oxide, interleukin-6 (IL-6),
and tumor necrosis factor-a (TNF-a) by rat peritoneal macrophages.
Group NOi (pM) IL-6 (U/mL) TNF-a* (U/mL)
U74389Fveb 78.2 1500 <5
+ U74389F, 10 11M 68.3 800 <5
HKP 92.5 72,960 85
+ U74389F, 1 11M 92.9 101,120 120
+ U74389F, 10 11M 85.4 70,400 68
+ U74389F, 100 11M 79.3 24,320 9
LPS 95.6 8640 20
+ U74389F, 10 f.1M 90.0 4960 <5
+ U74389F, 100 f.1M 84.5 2050 <5
Interferon-y + TNF-a 94.6 1650 ND
+ U74389F, 100 f.1M 78.2 260 ND
NOTE. NOi = nitrite; veh = vehicle of U74389F; HKP = heat-killed pneumococci (10 7 cfu/mL); LPS
Escherichia coli lipopolysaccharide; ND = not done.
* Detection limit of TNF-a assay was 5 U/mL.
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content. The anti edematous effect of U74389F when given
prior to infection corresponds with findings in other pathophys-
iologic CNS models that documented a protective effect of 21-
amino steroids on brain edema formation [19]. The increase in
ICP in the early phase of experimental pneumococcal meningi-
tis is thought to be mainly due to an increase in brain water
content and an increase in cerebral blood volume [20]. Our
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had no effect on CSF pleocytosis (7240 ± 700 vs. 6710 ± 729
cells/pL), rCBF (189.3% ± 13.3% vs. 211.6% ± 5.2%), or
brain water content (79.04% ± 0.03% vs. 79.09% ± 0.03%).
Administration of L-NA 4 h after infection in U74389F-pre-
treated rats (group 6) produced an increase in MABP from 98 ±
4 to 124 ± 5 rom Hg. The rCBF increase at 4 h after infection
(149.1% ± 14.4% for group 6 vs. 151.8% ± 7.0% for group 2)
was completely reversed by L-NA (97.4% ± 12.8% for group 6
vs. 167.7% ± 3.4% for group 2 5 h after infection).
Inhibition of release ofNO, 1L-6, and TNF-a by peritoneal
macrophages stimulated with HKP, E. coli LPS, and cytokines.
HKP (in a dose-dependent fashion, data shown only for 107
cfu/mL), E. coli LPS, and murine rIFN-y plus murine rTNF-
a stimulated production of NO, IL-6, and TNF-a in the macro-
phage cultures (table 2). U74389F inhibited dose dependently
NO, IL-6, and TNF-a production by macrophages stimulated
with HKP, E. coli LPS, or murine rIFN-y plus murine rTNF-
a. HKP (10 7 cfu/mL)-induced production of NO, IL-6, and
TNF-a by macrophages was inhibited by U74389F (100 J-lM)
by 92%, 89%, and 67%, respectively.
Inhibition of lipid peroxidation by U74389F in primary
astrocytes. Iron-dependent lipid peroxidation in primary rat
























The major finding of this study was that pretreatment with
the novel 21-aminosteroid U74389F significantly attenuated
increases in brain water content and ICP and CSF leukocytosis
during the early phase of experimental pneumococcal meningi-
tis in the rat. U74389F had no effect on the increase in rCBF.
Administration ofU74389F to animals with established menin-
gitis significantly attenuated the increase in ICP but had no
effect on CSF pleocytosis or increases in rCBF and brain water
Figure 2. Inhibition of iron-dependent lipid peroxidation in pri-
mary rat astrocytes. Lipid peroxidation was assessed by formation of
thiobarbituric acid (TBA)-reactive substances (mean ± 99% confi-
dence interval). Addition of Fe2+IFe3+ (+ vehicle of U74389F [veh.j]
or methylprednisolone [vehMD to astrocytes induced significant in-
crease of TBA-reactive substances vs. action of diluent of Fe2 +/Fe3+
(control; * P < .05). Increase was significantly attenuated by methyl-
prednisolone, known inhibitor of lipid peroxidation (§ t , P < .05 vs.
veh., and 1 mM, respectively). U74389F also blocked increase of
TBA-reactive substances (# +, P < .05 vs. veh., and vs. 0.1 and 10
mM, respectively. All P values determined by analysis of variance
and Student-Newman-Keuls multiple comparisons.
JID 1995; 172 (July) 21-Aminosteroid in Pneumococcal Meningitis 117
inhibited might be explained by the lack of influence of
U74389F on an increase in rCBF, which, in tum, may be caused
at least in part by an increase in cerebral blood volume.
The 21-aminosteroids exhibit protective effects in a variety
ofpathologic conditions, including cerebral ischemia [21], sub-
arachnoid hemorrhage [22], traumatic brain injury [23], vaso-
genic edema [19], and endotoxemia [24]. Their protective ef-
fects have been primarily attributed to their capacity to inhibit
membrane lipid peroxidation [12, 25] . We investigated whether
U74389F is capable of inhibiting iron-dependent lipid peroxi-
dation in a CNS cell culture system. Our in vitro experiments
used primary rat astrocytes and showed that the ability of
U74389F to suppress lipid peroxidation is comparable to that
of methylprednisolone, a potent inhibitor of lipid peroxidation.
By inhibiting lipid peroxidation, the 21-aminosteroids may in-
directly exert further inhibitory actions. For example, inhibition
of 5-lipoxygenase may prevent the formation of leukotrienes
[19], inhibition ofNADPH oxidase may prevent the generation
of superoxide radical and hydrogen peroxide [26], and inhibi-
tion of the destruction of cell membranes may prevent the
release of arachidonic acid [27]. Recently, others have sug-
gested that some 21-aminosteroids (e.g., U74389F, U78518F)
may have an oxygen radical scavenging effect [28, 29].
We tested whether U74389F, apart from inhibiting lipid per-
oxidation, also interferes with other mediators (e.g., cytokines
and NO) known to be involved in the pathophysiology ofbacte-
rial meningitis [4,30, 31]. Peritoneal macrophages, which we
used in our in vitro experiments, are an established cell culture
system for the induction of cytokines and NO. There are simi-
larities between rat peritoneal macrophages and brain macro-
phages and microglia: Both cell types produce cytokines [32,
33] and NO [34, 35] upon stimulation with LPS and Staphylo-
coccus aureus. Our data provide evidence that the activity of
U74389F is not restricted to inhibition of lipid peroxidation.
U74389F inhibited the production of NO, IL-6, and TNF-a by
rat peritoneal macrophages stimulated with heat-killed pneu-
mococci, E. coli LPS, and cytokines. A previous study showed
that another 21-aminosteroid compound (U74500A) interferes
with the production of cytokines [36]. Our in vitro studies
showed that U74389F inhibited NO production by rat perito-
neal macrophages; however, in vivo, U74389F (in two different
dosages) surprisingly had no effect on blood flow changes,
which are known to be NO-mediated [30, 31]. Thus, in our
meningitis model, U74389F did not affect NO production, al-
though the addition ofthe NO synthase inhibitor L-NA reversed
the blood flow increase.
We found that U74389F reduced meningeal inflammation.
This observation is consistent with a recent study in which the
21-aminosteroid tirilazad mesylate attenuated the accumulation
of neutrophils in ischemic gerbil brain [37]. In contrast, others
have reported that U74389F does not inhibit the hyperoxia-
induced accumulation of neutrophils in bronchoalveolar lavage
fluid [38]. One explanation for the effect observed in our study
may be that 21-aminosteroids inhibit the generation of superox-
ide radical and thereby reduce the expression of adhesive glyco-
proteins [39, 40] and the adherence of neutrophils. Another
explanation might be that damage of biomembranes by lipid
peroxidation could lead to the release of chemoattractant sub-
stances, such as arachidonic acid metabolites or platelet-activat-
ing factor, which could be prevented by inhibitors of lipid
peroxidation.
Reactive oxygen species are known to play a role in early
pathophysiologic changes during experimental bacterial men-
ingitis [6-10]. Along with the data from our previous experi-
ments, the results of the current study suggest that lipid per-
oxidation induced by oxygen free radicals is involved in the
pathophysiologic mechanisms during the early phase of pneu-
mococcal meningitis. However, other activities of the 21-
amino steroid U74389F, such as interference with cytokine pro-
duction, might contribute to the modulation of the pathophysio-
logic changes in early experimental pneumococcal meningitis.
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